Document:

EX-10.7

 Exhibit 10.7 
  

			
	

	 	 200 Powder Mill Road

Experimental Station E400/3213

Wilmington, DE 19803

 March 21, 2019 
 Andrew P.
Combs 
 Dear Andy: 
 On behalf of Prelude Therapeutics
Incorporated (“Prelude”), I am pleased to confirm our offer to you for the position of Executive Vice President and Head of Chemistry subject to the terms and conditions outlined in this offer letter. The terms of your employment will be
as follows: 
 Position and Duties 
 Beginning on
April 1, 2019, you will serve as Executive Vice President and Head of Chemistry reporting to Kris Vaddi, Chief Executive Officer and will perform your services at our Prelude’s offices at the Experimental Station in Wilmington, Delaware,
except when you will be required to travel for business purposes. Notwithstanding the foregoing, you will be permitted to: (1) manage your personal passive investments and (2) remain on the scientific advisory boards or equivalent bodies
of Boston University CMD, University of Delaware Cobre, and University of Pittsburg Wipf Chemistry, in each case, so long as they do not interfere with the performance of your duties to the Company or violate any other agreement to which you are
now, or hereafter may become, party to with the Company. 
 Base Salary 

Your annual base salary will be $250,000, paid in periodic installments in accordance with Prelude’s payroll policies. You will first become eligible to
be considered for a merit increase in January 2020. Salary adjustments are in the discretion of the Company and are based upon a variety of factors including, without limitation, Company performance, individual performance, and competitive salaries.
All payments made to you shall be subject to applicable tax withholdings and deductions. 
 Bonus 

You will be eligible to participate in the Company’s performance bonus program. The target bonus for your position is 35% of your base salary (pro-rated in your initial year of hire). The amount of your actual bonus will be based primarily upon your achievement of individual performance objectives and the Company’s meeting corporate targets, each as
established by the Chief Executive Officer or the Board of Directors. The performance bonus (if any) generally shall be paid within three months after year-end. In order to receive a performance bonus, you
must be employed by the Company on the bonus payment date. 
 Restricted Stock Award 

You will be awarded 300,000 shares of restricted common stock of Prelude, subject to Board approval. Subject to continuing employment, the shares will vest
over four years from the date of grant, 25% of the total will vest on 

 
each of the first, second third and fourth anniversary of the date of grant. Such restricted stock grant, if approved, will be subject to the terms and conditions established within the
Company’s Equity Plan and a separate stock grant agreement between you and the Company that sets forth the terms of the grant (e.g., number of shares, expiration date, and vesting schedule). 

Benefits 
 You will be eligible to participate in the
employee benefit plans that Prelude generally makes avail able to its full-time employees, subject to the terms and conditions of such plans, to the extent adopted and in effect after the date hereof. Prelude will reimburse the employees 80% of the
cost of the premium for health insurance to cover medical and dental coverages, if needed. Furthermore, you will be eligible for 20 days of paid time off (PTO) each year. For 2019, your PTO allotment will be prorated based on your hire date. Upon
the termination of your employment for any reason, Prelude will pay you for any accrued but unused PTO time. 
 Conditions 

This offer, and your employment pursuant to this offer, is conditioned upon the following: 

 

	•	 	 Your return of this signed, unmodified letter to me no later than March 22 , 2019. 

 

	•	 	 Your ability to start work with Prelude on or before April 1, 2019. 

 

	•	 	 Your execution of, and ongoing compliance with, the terms of a Confidentiality, Restrictive Covenant and
Inventions Assignment Agreement. 

  

	•	 	 Your delivery of and satisfactory review by Prelude of any restrictive covenant agreements to which you are
subject, including any agreement containing non-competition restrictions or other provisions that would in any way preclude you from accepting this offer and working for Prelude or that would limit such
employment. 

  

	•	 	 Verification of your right to work in the United States. The 1986 Immigration Reform and Control Act required
U.S. employers to ensure that all candidates for employment are legally authorized to work in the country. Therefore, you must furnish identification proving US Citizenship or authorization to work in the US. 

All employees of Prelude are employed on an at-will basis, which means that either you or Prelude may terminate your
employment by Prelude at any time. Our offer should not be construed as a guarantee of employment for any specific duration. 
 If you have any questions
regarding this offer, please contact me. If not, please sign this letter to indicate your acceptance of the offer and return it to me by March 22, 2019. 

We look forward to you accepting this offer and building a mutually rewarding relationship at Prelude. 

 

	
	Sincerely,
	
	/s/ Kris Vaddi
	Kris Vaddi
	 Chief Executive Officer
 Prelude
Therapeutics

  

	
	Agreed and accepted, this 28th day of March, 2019
	
	By: /s/ Andrew P. CombsEX-10.8

 Exhibit 10.8 
  

					
	

	  		  	 200 Powder Mill Road

Experimental Station E400/3213
Wilmington, DE 19803

 April 4, 2019 

Dr. David Mauro, MD, PhD 
 Dear David: 

On behalf of Prelude Therapeutics Incorporated (“Prelude”), I am pleased to confirm our offer to you for the position of Chief Medical Officer
subject to the terms and conditions outlined in this offer letter. The terms of your employment will be as follows: 
 Position and Duties 

Beginning on April 29, 2019, you will serve as Chief Medical Officer reporting to Kris Vaddi, Chief Executive Officer and will perform your services at
our Prelude’s offices at the Experimental Station in Wilmington, Delaware, except when you will be required to travel for business purposes. Your services may be periodically performed offsite based on the mutual agreement between yourself and
the Chief Executive Officer. 
 Base Salary 
 Your
annual base salary will be $375,000, paid in periodic installments in accordance with Prelude’s payroll policies. You will first become eligible to be considered for a merit increase in January 2020. Salary adjustments are in the discretion of
the Company and are based upon a variety of factors including, without limitation, Company performance, individual performance, and competitive salaries. All payments made to you shall be subject to applicable tax withholdings and deductions. 

Bonus 
 You will be eligible to participate in the
Company’s performance bonus program. The target bonus for your position is 35% of your base salary (pro-rated in your initial year of hire). The amount of your actual bonus will be based upon your
achievement of individual performance objectives and the Company’s achievement of corporate targets, each as established by the Chief Executive Officer or the Board of Directors. The performance bonus (if any) generally shall be paid within
three months after year-end. In order to receive a performance bonus, you must be employed by the Company on the bonus payment date. 

Stock Option Award 
 You will be awarded a stock option to
purchase 350,000 shares of common stock of Prelude, subject to Board approval. Subject to continuing employment, the options will vest over four years from the date of grant with 25% of the total vesting on the first anniversary of your start date
and the remainder vesting in equal monthly amounts over the next 36 months. Such stock option grant, if approved, will be subject to the terms and conditions established within the Company’s Equity Plan and a separate stock option agreement
between you and the Company that sets forth the terms of the grant (e.g., number of shares, expiration date, and vesting schedule). 

 Benefits 

You will be eligible to participate in the employee benefit plans that Prelude generally makes available to its full-time employees, subject to the terms and
conditions of such plans, to the extent adopted and in effect after the date hereof. Furthermore, you will be eligible for 20 days of paid time off (PTO) each year. For 2019, your PTO allotment will be prorated based on your hire date. Upon the
termination of your employment for any reason, Prelude will pay you for any accrued but unused PTO time. 
 Severance 

In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (1) your then-existing
Base Salary through the date of termination (2) an amount equal to the value of any accrued unused paid time off that is required by law to be cashed out, and (3) the amount of any expenses properly incurred by you on behalf of the Company
prior to any such termination and not yet reimbursed, subject to the terms and conditions of the Company expense and reimbursement policies, as in effect from time to time. In addition, in the event the Company terminates your employment without
Cause (as defined below), the Company shall provide you with the following termination benefits: 
  

	 	(i)	 continuation of your then-existing Base Salary for a period of 9 months after the date of termination at the
salary rate then in effect (“Salary Continuation Payments”) (solely for purposes of Section 409A on the Internal Revenue Code of 1986, as amended, each Salary Continuation Payment is considered a separate payment); and

  

	 	(ii)	 continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C § 1161
et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of the termination until the earlier of (i) six (6)
months from the termination date; and (ii) the date you become eligible for health insurance benefits through another employer or otherwise become ineligible for COBRA; provided that, if the Company determines in its sole discretion that it
cannot provide the COBRA benefits described herein without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide you with a taxable lump sum payment in
an amount equal to the then unreimbursed monthly COBRA premiums, which lump sum payment will be made on the first regular payroll date after the 60th day following your termination of employment. 

In the event the Company terminates your employment without Cause or you resign for Good Reason (as defined below), in each case in connection with or within
12 months following a Sale of the Company (as defined in the Company’s Voting Agreement), in lieu of the Salary Continuation Payments described above, the Company will make you a lump sum payment equal to 9 months of your then-existing Base
Salary within 60 days of such termination (“Lump-Sum Severance”) and will fully accelerate the vesting of all outstanding Company stock options. 

Payment of any form of severance or equity acceleration is subject to execution of a release of claims in a form satisfactory to the Company at time of
termination, and such release becoming effective. 
 The Salary Continuation Payments shall commence the first payroll date after the 60th day following the date of termination (with payment of all amounts accrued through such date) and shall be made thereafter on the Company’s regular payroll dates. 

“Cause” means any of the following: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross
negligence, misconduct, neglect of duties, theft, fraud or breach of fiduciary duty to the Company; (iii) violation of federal and state securities laws; (iv) your breach of this offer letter, the Confidential Information Agreement or any
other agreement between you and Company; (v) commission of or conviction of a felony, or any crime; (vi) your intentional breach of any written Company policy that has a material adverse effect on the Company or (vii) refusal to
perform the duties assigned to you under or pursuant to this Agreement, which refusal has not been cured by you after having been given thirty (30) calendar days’ advance written notice by the Company of such a breach. 

 “Good Reason” means that you have complied with the “Good Reason Process” (hereinafter
defined) following the occurrence of any part of the following actions undertaken by the Company without your express prior written consent: (i) the material diminution in your responsibilities, authority and function; (ii) a material
reduction in your Base Salary, provided that Good Reason shall not be deemed to have occurred in the event of a reduction in your Base Salary that is pursuant to a salary reduction program affecting all of the senior management of the Company and
that does not adversely effect you to a greater extent than other similarly situated executives; or (iii) a change of 50 miles or more in the geographic location at which you must regularly report to work and perform services, except for
required travel on the Company’s business. “Good Reason Process” means that (i) you have reasonably determined in good faith that a “Good Reason condition has occurred; (ii) you have notified the Company in writing of
the first occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition; (iii) you have cooperated in good faith with the Company’s efforts , for a period not less than thirty (30) days
following such notice (“Cure Period”) to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exits; and (v) you terminate your employment within sixty (60) days after the end of
the Cure Period if such condition remains uncured. 
 Conditions 

This offer, and your employment pursuant to this offer, is conditioned upon the following: 

 

	 	•	 	 Your return of this signed, unmodified letter to me no later than April 5, 2019. 

 

	 	•	 	 Your ability to start work with Prelude on or before April 29, 2019. 

 

	 	•	 	 Your execution of, and ongoing compliance with, the terms of a Confidentiality, Restrictive Covenant and
Inventions Assignment Agreement. 

  

	 	•	 	 Your delivery of and satisfactory review by Prelude of any restrictive covenant agreements to which you are
subject, including any agreement containing non-competition restrictions or other provisions that would in any way preclude you from accepting this offer and working for Prelude or that would limit such
employment. 

  

	 	•	 	 Verification of your right to work in the United States. The 1986 Immigration Reform and Control Act required
U.S. employers to ensure that all candidates for employment are legally authorized to work in the country. Therefore, you must furnish identification proving US Citizenship or authorization to work in the US. 

All employees of Prelude are employed on an at-will basis, which means that either you or Prelude may terminate your
employment by Prelude at any time. Our offer should not be construed as a guarantee of employment for any specific duration. 
 If you have any questions
regarding this offer, please contact me. If not, please sign this letter to indicate your acceptance of the offer and return it to me by April 5, 2019. 

We look forward to you accepting this offer and building a mutually rewarding relationship at Prelude. 

Sincerely, 

	
	
	/s/ Kris Vaddi
	Kris Vaddi
	Chief Executive Officer
	Prelude Therapeutics

  

			
	Agreed and accepted, this 4 day of April, 2019
		
	By:	 	/s/ David Mauro

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]